Free Trial
→ I’m sounding the alarm (From Porter & Company) (Ad)tc pixel Free VRDN Stock Alerts

Viridian Therapeutics (VRDN) Financials

Viridian Therapeutics logo
$17.43 +0.39 (+2.29%)
Closing price 04:00 PM Eastern
Extended Trading
$17.48 +0.05 (+0.29%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Viridian Therapeutics

Annual Income Statements for Viridian Therapeutics

This table shows Viridian Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -11 -17 -27 -33 -42 -111 -79 -130 -238 -270 -343
Consolidated Net Income / (Loss)		 -11 -17 -27 -33 -42 -111 -79 -130 -238 -270 -343
Net Income / (Loss) Continuing Operations		 -11 -17 -27 -33 -42 -111 -79 -130 -238 -270 -343
Total Pre-Tax Income 		-11 -17 -27 -34 -43 -111 -79 -130 -238 -270 -343
Total Operating Income		 -11 -17 -27 -33 -42 -110 -80 -134 -254 -299 -363
Total Gross Profit		 0.07 3.48 4.00 8.39 4.46 1.05 2.96 1.77 0.31 0.30 71
Total Revenue		 2.54 3.48 4.00 8.39 4.46 1.05 2.96 1.77 0.31 0.30 71
Operating Revenue		 2.54 3.48 4.00 8.39 4.46 1.05 2.96 1.77 0.31 0.30 71
Total Cost of Revenue		 2.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 11 20 31 41 46 111 83 136 255 299 434
Selling, General & Admin Expense		 7.69 6.77 11 11 12 13 26 35 95 61 95
Research & Development Expense		 1.00 14 20 30 35 98 57 101 160 238 339
Total Other Income / (Expense), net		 -0.14 -0.33 -0.38 -0.87 -0.84 -0.51 0.32 4.43 17 29 21
Interest Expense		 0.14 0.33 0.38 0.87 0.84 0.51 0.00 0.49 1.33 2.20 4.95
Interest & Investment Income		 - - - - - - 0.32 4.92 18 32 27
Other Income / (Expense), net		 - - - - - - - - -0.19 -0.31 -1.66
Basic Earnings per Share		 ($21.02) ($28.21) ($1.38) ($1.10) ($20.04) ($31.13) ($6.66) ($364.59) ($525.30) ($412.71) ($446.62)
Weighted Average Basic Shares Outstanding		 539.46K 614.02K 19.24M 29.60M 2.09M 3.56M 11.92M 32.32M 45.00M 68.19M 85.08M
Diluted Earnings per Share		 ($21.02) ($28.21) ($1.38) ($1.10) ($20.04) ($31.13) ($6.66) ($364.59) ($525.30) ($412.71) ($446.62)
Weighted Average Diluted Shares Outstanding		 539.46K 614.02K 19.24M 29.60M 2.09M 3.56M 11.92M 32.32M 45.00M 68.19M 85.08M
Weighted Average Basic & Diluted Shares Outstanding		 539.46K 614.02K 19.24M 29.60M 2.09M 3.56M 25.91M 42.90M 62.77M 81.48M 102.21M

Quarterly Income Statements for Viridian Therapeutics

This table shows Viridian Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -48 -67 -49 -65 -77 -80 -87 -101 -35 -120 -105
Consolidated Net Income / (Loss)		 -48 -67 -49 -65 -77 -80 -87 -101 -35 -120 -105
Net Income / (Loss) Continuing Operations		 -48 -67 -49 -65 -77 -80 -87 -101 -35 -120 -105
Total Pre-Tax Income 		-48 -67 -49 -65 -77 -80 -87 -101 -35 -120 -105
Total Operating Income		 -51 -71 -56 -72 -83 -87 -94 -107 -40 -123 -116
Total Gross Profit		 0.07 0.17 0.07 0.07 0.09 0.14 0.07 0.08 71 0.13 0.14
Total Revenue		 0.07 0.17 0.07 0.07 0.09 0.14 0.07 0.08 71 0.13 0.14
Operating Revenue		 0.07 - 0.07 0.07 0.09 - 0.07 0.08 71 0.13 0.14
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 51 72 56 72 84 88 94 107 111 123 116
Selling, General & Admin Expense		 21 33 15 16 14 16 17 20 24 34 39
Research & Development Expense		 30 39 41 56 69 72 77 87 86 89 78
Total Other Income / (Expense), net		 3.56 4.62 7.36 7.19 6.79 7.75 6.95 6.03 5.41 2.39 11
Interest Expense		 0.60 0.92 0.59 0.60 0.53 0.86 0.55 0.51 0.56 3.29 3.46
Interest & Investment Income		 4.16 5.53 7.94 7.79 7.52 8.60 7.54 6.55 5.52 7.79 7.87
Other Income / (Expense), net		 - - - - -0.20 - -0.04 - 0.45 - 6.86
Basic Earnings per Share		 ($1.09) ($521.33) ($79.48) ($104.04) ($118.85) ($409.75) ($116.75) ($134.97) ($46.26) ($148.64) ($120.94)
Weighted Average Basic Shares Outstanding		 43.65M 45.00M 61.41M 64.16M 66.72M 68.19M 81.62M 81.87M 82.06M 85.08M 102.43M
Diluted Earnings per Share		 ($1.09) ($521.33) ($79.48) ($104.04) ($118.85) ($409.75) ($116.75) ($134.97) ($46.26) ($148.64) ($120.94)
Weighted Average Diluted Shares Outstanding		 43.65M 45.00M 61.10M 63.85M 66.42M 68.19M 81.34M 81.87M 82.06M 85.08M 102.43M
Weighted Average Basic & Diluted Shares Outstanding		 52.59M 62.77M 63.82M 63.89M 79.21M 81.48M 81.59M 81.66M 95.44M 102.21M 103.07M

Annual Cash Flow Statements for Viridian Therapeutics

This table details how cash moves in and out of Viridian Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 5.71 0.87 25 -15 -7.76 21 -3.60 113 -53 -3.23 113
Net Cash From Operating Activities		 -6.90 -15 -28 -27 -36 -30 -55 -94 -184 -232 -276
Net Cash From Continuing Operating Activities		 -6.90 -15 -28 -27 -36 -30 -55 -94 -184 -232 -276
Net Income / (Loss) Continuing Operations		 -11 -17 -27 -33 -42 -111 -79 -130 -238 -270 -343
Consolidated Net Income / (Loss)		 -11 -17 -27 -33 -42 -111 -79 -130 -238 -270 -343
Depreciation Expense		 0.18 0.30 0.30 0.28 0.29 0.24 0.12 0.26 0.52 0.54 0.46
Amortization Expense		 - - 0.00 -0.42 -0.43 0.34 1.05 0.02 -11 -16 -6.76
Non-Cash Adjustments To Reconcile Net Income		 2.90 0.64 2.50 4.05 4.31 76 21 20 74 43 49
Changes in Operating Assets and Liabilities, net		 1.35 1.54 -4.47 1.94 1.65 4.43 2.18 16 -9.43 9.60 23
Net Cash From Investing Activities		 -0.10 -0.25 1.03 -30 28 -50 -74 -115 -94 -229 -38
Net Cash From Continuing Investing Activities		 -0.10 -0.25 1.03 -30 28 -50 -74 -115 -94 -229 -38
Purchase of Property, Plant & Equipment		 -0.12 -0.25 -0.25 -0.45 -0.08 -0.04 -0.34 -0.80 -0.90 -0.51 -0.50
Purchase of Investments		 - -1.00 0.00 -62 -33 -82 -188 -223 -408 -695 -579
Sale and/or Maturity of Investments		 - 1.00 0.00 33 61 2.00 114 109 315 467 542
Net Cash From Financing Activities		 13 16 52 42 0.07 101 125 322 226 458 427
Net Cash From Continuing Financing Activities		 13 16 52 42 0.07 101 125 322 226 458 427
Repayment of Debt		 -0.08 -0.34 -4.67 0.00 -2.33 -10 0.00 -0.45 -0.51 0.00 -0.48
Repurchase of Common Equity		 0.00 - -1.85 -3.04 -0.08 -6.18 -8.28 -22 -12 -27 -19
Issuance of Debt		 0.05 0.00 10 0.24 0.00 1.73 0.00 5.00 15 0.00 84
Issuance of Preferred Equity		 - 16 - - 0.00 91 17 44 76 25 0.00
Issuance of Common Equity		 13 - 49 45 2.48 25 114 293 128 454 355
Other Financing Activities, net		 -0.36 0.20 0.30 0.18 0.00 -0.04 2.31 2.76 19 5.34 7.07
Cash Interest Paid		 0.01 0.16 0.45 0.49 0.51 0.27 0.00 0.29 0.89 1.82 2.15

Quarterly Cash Flow Statements for Viridian Therapeutics

This table details how cash moves in and out of Viridian Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 25 -8.77 24 16 93 -101 17 1.11 48 43 -36
Net Cash From Operating Activities		 -39 -38 -45 -46 -68 -73 -93 -75 -85 -24 -120
Net Cash From Continuing Operating Activities		 -39 -37 -45 -46 -68 -73 -93 -75 -85 -24 -120
Net Income / (Loss) Continuing Operations		 -48 -67 -49 -65 -77 -80 -87 -101 -35 -120 -105
Consolidated Net Income / (Loss)		 -48 -67 -49 -65 -77 -80 -87 -101 -35 -120 -105
Depreciation Expense		 0.14 0.15 0.15 0.14 0.13 0.12 0.12 0.11 0.11 0.12 0.12
Amortization Expense		 -2.45 -2.94 -4.54 -4.29 -3.31 -3.15 -2.32 -1.45 -1.34 -1.75 -1.86
Non-Cash Adjustments To Reconcile Net Income		 15 27 13 12 9.18 8.97 10 11 -58 87 8.37
Changes in Operating Assets and Liabilities, net		 -4.08 5.62 -4.96 11 2.98 0.45 -14 16 9.67 11 -21
Net Cash From Investing Activities		 48 -170 -143 62 -85 -63 100 76 126 -339 77
Net Cash From Continuing Investing Activities		 48 -170 -143 62 -85 -63 100 76 126 -339 77
Purchase of Property, Plant & Equipment		 -0.40 -0.05 0.00 -0.10 -0.29 -0.11 -0.09 -0.04 -0.13 -0.24 -0.02
Purchase of Investments		 -50 -272 -226 -59 -228 -182 -71 -56 -14 -438 -91
Sale and/or Maturity of Investments		 98 103 83 121 144 119 171 132 140 99 169
Net Cash From Financing Activities		 15 199 177 0.11 245 36 9.21 0.76 11 406 6.36
Net Cash From Continuing Financing Activities		 15 199 212 0.11 245 36 9.21 0.76 6.06 406 6.36
Repurchase of Common Equity		 - -12 -10 -0.10 -15 -1.31 -0.21 - -0.21 -18 0.00
Issuance of Common Equity		 0.26 201 222 - 234 34 7.12 0.00 5.72 337 0.00
Other Financing Activities, net		 0.71 9.48 0.84 0.21 1.11 3.19 2.30 0.76 0.55 3.47 6.36
Cash Interest Paid		 0.21 0.45 0.45 0.46 0.46 0.45 0.45 0.46 0.46 0.79 1.12

Annual Balance Sheets for Viridian Therapeutics

This table presents Viridian Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 13 25 52 66 30 131 204 435 490 742 899
Total Current Assets		 12 24 52 65 30 130 200 431 486 738 894
Cash & Equivalents		 11 22 47 33 25 46 42 156 103 100 212
Short-Term Investments		 - - 0.00 30 2.00 82 155 269 375 618 662
Prepaid Expenses		 0.32 1.75 2.97 2.87 2.89 1.97 2.75 6.52 9.01 21 20
Plant, Property, & Equipment, net		 1.15 0.63 0.56 0.73 0.52 0.31 0.38 1.33 1.67 1.24 1.23
Total Noncurrent Assets		 0.02 0.26 0.05 0.05 0.00 1.34 3.17 2.59 2.27 2.71 3.96
Other Noncurrent Operating Assets		 0.02 0.26 0.05 0.05 0.00 1.34 3.17 2.59 2.27 2.71 3.96
Total Liabilities & Shareholders' Equity		 13 25 52 66 30 131 204 435 490 742 899
Total Liabilities		 2.49 9.71 14 15 15 11 16 40 48 71 177
Total Current Liabilities		 2.47 6.89 3.90 6.73 10 11 14 33 27 48 71
Accounts Payable		 0.24 1.01 0.91 0.57 1.10 0.67 2.33 14 2.24 2.14 8.68
Accrued Expenses		 1.02 3.91 2.99 3.87 5.11 9.70 11 19 24 46 62
Total Noncurrent Liabilities		 0.02 2.82 10 8.07 4.33 0.54 2.36 6.68 22 23 107
Long-Term Debt		 - 2.82 9.92 8.00 4.33 - - 4.65 20 21 84
Other Noncurrent Operating Liabilities		 0.02 0.00 0.15 0.07 0.00 0.54 1.21 1.17 0.99 2.31 22
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 10 -62 39 51 16 120 188 395 442 672 722
Total Preferred & Common Equity		 10 -62 39 51 16 120 188 395 442 672 722
Preferred Stock		 0.00 - - - 0.00 181 134 142 207 189 132
Total Common Equity		 10 -62 39 51 16 -61 54 253 236 483 590
Common Stock		 28 5.16 132 178 184 218 412 741 961 1,479 1,928
Retained Earnings		 -18 -67 -94 -126 -168 -279 -358 -488 -726 -996 -1,338
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.00 0.00 -0.01 -0.16 -0.39 0.34 -0.01 0.45

Quarterly Balance Sheets for Viridian Therapeutics

This table presents Viridian Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 441 387 351 329 630 586 772 661 582 577 789
Total Current Assets		 437 383 346 324 627 582 767 657 579 572 785
Cash & Equivalents		 344 89 87 112 92 108 200 116 117 170 176
Short-Term Investments		 87 285 247 201 522 464 553 520 446 321 586
Prepaid Expenses		 5.64 8.62 12 11 14 10 14 21 15 11 23
Plant, Property, & Equipment, net		 0.83 1.59 1.88 1.80 1.53 1.51 1.29 1.16 1.09 1.13 1.13
Total Noncurrent Assets		 2.40 2.45 3.25 3.12 2.04 2.49 3.25 2.58 2.48 4.10 3.14
Other Noncurrent Operating Assets		 2.40 2.45 3.25 3.12 2.04 2.49 3.25 2.58 2.48 4.10 3.14
Total Liabilities & Shareholders' Equity		 441 387 351 329 630 586 772 661 582 577 789
Total Liabilities		 32 36 36 45 48 56 64 57 67 74 153
Total Current Liabilities		 25 30 29 23 26 37 41 34 53 51 52
Accounts Payable		 12 7.87 4.13 3.74 2.68 3.14 6.34 3.89 8.52 10 13
Accrued Expenses		 13 21 24 19 23 30 35 30 35 41 38
Total Noncurrent Liabilities		 6.36 6.51 6.95 22 22 20 23 23 15 23 101
Long-Term Debt		 4.61 4.68 4.71 20 20 17 21 21 12 21 87
Other Noncurrent Operating Liabilities		 0.81 1.04 1.53 1.29 0.90 1.65 2.16 1.88 2.08 2.58 15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 409 351 316 284 583 529 707 604 515 503 636
Total Preferred & Common Equity		 409 351 316 284 583 529 707 604 515 503 636
Preferred Stock		 142 135 135 135 200 200 189 189 189 189 132
Total Common Equity		 267 216 181 149 383 330 519 416 326 314 504
Common Stock		 710 772 793 808 1,158 1,170 1,434 1,498 1,510 1,532 1,948
Retained Earnings		 -442 -556 -611 -659 -774 -839 -916 -1,083 -1,184 -1,218 -1,443
Accumulated Other Comprehensive Income / (Loss)		 -0.94 -0.17 -0.17 -0.06 -0.37 -0.54 0.93 0.25 0.07 0.36 -0.56

Annual Metrics And Ratios for Viridian Therapeutics

This table displays calculated financial ratios and metrics derived from Viridian Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -41.25% 37.00% 15.13% 109.49% -46.80% -76.46% 182.19% -40.20% -82.28% -3.82% 23,359.93%
EBITDA Growth		 -63.66% -51.66% -57.20% -26.64% -26.80% -160.67% 28.46% -70.62% -97.79% -18.36% -18.09%
EBIT Growth		 -62.91% -51.85% -56.19% -24.69% -26.89% -162.94% 27.77% -68.45% -89.46% -17.52% -21.95%
NOPAT Growth		 -62.91% -51.85% -56.19% -24.69% -26.89% -162.94% 27.77% -68.45% -89.46% -17.52% -21.52%
Net Income Growth		 -43.57% -52.49% -53.48% -23.35% -28.04% -164.41% 28.27% -63.54% -83.05% -13.55% -26.91%
EPS Growth		 -43.57% -34.21% 95.11% 20.29% -28.04% -55.34% 78.61% -5,374.32% -44.08% 21.43% -8.22%
Operating Cash Flow Growth		 -211.70% -113.90% -90.90% 4.70% -34.32% 17.41% -83.29% -71.92% -96.26% -26.14% -18.97%
Free Cash Flow Firm Growth		 -111.69% -17.09% -143.89% 2.27% -28.64% -164.06% 25.24% -44.79% -139.49% -6.01% -6.19%
Invested Capital Growth		 -21.67% -430.89% 143.85% -184.66% -232.18% -172.77% -21.67% -168.58% 39.04% -67.49% -169.29%
Revenue Q/Q Growth		 0.16% -4.11% 20.57% -7.87% 9.96% -44.03% 5.71% 9.05% -37.82% 2,057.14% 0.08%
EBITDA Q/Q Growth		 -6.71% -21.95% -1.42% -14.81% 1.28% -274.34% 44.02% -18.65% -10.18% -5.45% -10.69%
EBIT Q/Q Growth		 -6.69% -21.08% -1.69% -14.14% 0.90% -269.75% 43.55% -17.48% -9.66% -5.65% -11.26%
NOPAT Q/Q Growth		 -6.69% -21.08% -1.69% -14.14% 0.90% -269.75% 43.55% -17.48% -9.66% -5.65% -10.75%
Net Income Q/Q Growth		 -6.81% -20.97% -1.58% -13.66% 0.47% -211.13% 41.49% -14.90% -9.73% -5.00% -13.45%
EPS Q/Q Growth		 -6.81% -18.73% -14.05% -17.02% 0.47% -284.80% 47.27% -10,783.28% -10,490.73% -9,497.91% -9.38%
Operating Cash Flow Q/Q Growth		 -4.58% -15.57% -16.34% -3.60% 1.01% -5.79% -14.95% -22.94% -2.20% -17.94% 15.21%
Free Cash Flow Firm Q/Q Growth		 0.00% -3.48% -25.58% -0.93% 1.37% -227.36% 39.72% -9.61% -10.03% -9.19% 26.55%
Invested Capital Q/Q Growth		 -57.68% -613.64% 322.20% -311.87% -93.81% -3,644.83% -0.30% -40.33% -60.57% -0.56% -307.23%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 2.60% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -433.53% -479.93% -655.31% -396.12% -944.25% -10,457.52% -2,651.23% -7,563.83% -84,427.07% -103,898.34% -524.14%
Operating Margin		 -440.78% -488.55% -662.80% -394.51% -941.02% -10,512.38% -2,690.79% -7,579.23% -81,035.03% -99,018.21% -512.91%
EBIT Margin		 -440.78% -488.55% -662.80% -394.51% -941.02% -10,512.38% -2,690.79% -7,579.23% -81,035.03% -99,018.21% -515.25%
Profit (Net Income) Margin		 -446.34% -496.81% -662.30% -389.97% -938.65% -10,544.29% -2,680.16% -7,329.23% -75,711.47% -89,387.09% -483.57%
Tax Burden Percent		 100.00% 99.77% 98.50% 96.31% 97.80% 99.84% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.26% 101.92% 101.44% 102.64% 101.99% 100.46% 99.60% 96.70% 93.43% 90.27% 93.85%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,007.19% 0.00% 0.00% -30,472.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -960.08% 0.00% 0.00% -30,450.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 869.05% 0.00% 0.00% 30,399.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -138.14% -135.67% -98.99% -72.79% -124.81% -163.07% -51.61% -44.57% -56.80% -48.48% -49.16%
Cash Return on Invested Capital (CROIC)		 -982.88% 0.00% -2,202.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -106.59% -90.21% -68.70% -55.78% -87.09% -136.68% -47.60% -42.05% -54.99% -48.51% -44.47%
Return on Assets (ROA)		 -107.93% -91.73% -68.65% -55.14% -86.87% -137.09% -47.42% -40.66% -51.37% -43.79% -41.73%
Return on Common Equity (ROCE)		 -138.14% 274.43% 43.26% -72.79% -124.81% 54.05% 1.15% -23.46% -33.14% -31.27% -37.84%
Return on Equity Simple (ROE_SIMPLE)		 -108.82% 27.90% -68.84% -63.69% -265.79% -92.23% -42.30% -32.87% -53.78% -40.19% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.83 -12 -19 -23 -29 -77 -56 -94 -178 -209 -254
NOPAT Margin		 -308.55% -341.99% -463.96% -276.16% -658.72% -7,358.67% -1,883.55% -5,305.46% -56,724.52% -69,312.75% -359.04%
Net Nonoperating Expense Percent (NNEP)		 -47.11% -39.81% -28.96% -21.28% -35.31% -45.76% -14.54% -11.63% -13.60% -10.51% -11.86%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -23.52% -38.53% -30.24% -31.55%
Cost of Revenue to Revenue		 97.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 303.07% 194.77% 272.60% 131.76% 261.06% 1,263.33% 870.91% 1,985.44% 30,254.46% 20,226.16% 134.53%
R&D to Revenue		 39.48% 393.79% 490.21% 362.76% 779.96% 9,349.05% 1,919.88% 5,693.79% 50,880.57% 78,892.05% 478.38%
Operating Expenses to Revenue		 443.38% 588.55% 762.80% 494.51% 1,041.02% 10,612.38% 2,790.79% 7,679.23% 81,135.03% 99,118.21% 612.91%
Earnings before Interest and Taxes (EBIT)		 -11 -17 -27 -33 -42 -110 -80 -134 -254 -299 -365
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -17 -26 -33 -42 -110 -79 -134 -265 -314 -371
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.76 0.00 6.04 1.82 0.97 0.00 7.97 4.65 4.86 3.15 5.03
Price to Tangible Book Value (P/TBV)		 0.76 0.00 6.04 1.82 0.97 0.00 7.97 4.65 4.86 3.15 5.03
Price to Revenue (P/Rev)		 3.13 1.04 58.13 11.14 3.42 61.27 144.94 663.46 3,647.53 5,028.17 41.92
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 196.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 18.20 48.76 4.92 0.00 111.90 123.63 506.71 2,849.28 3,345.67 32.63
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.11 0.32 0.26 0.20 0.53 0.00 0.00 0.01 0.05 0.03 0.12
Long-Term Debt to Equity		 0.00 0.19 0.26 0.16 0.27 0.00 0.00 0.01 0.05 0.03 0.12
Financial Leverage		 -0.91 -1.06 -1.02 -1.00 -1.05 -1.08 -1.05 -1.06 -1.05 -1.04 -1.07
Leverage Ratio		 1.28 1.48 1.44 1.32 1.44 1.19 1.09 1.10 1.11 1.11 1.18
Compound Leverage Factor		 1.30 1.51 1.46 1.36 1.47 1.19 1.08 1.06 1.03 1.00 1.11
Debt to Total Capital		 9.60% 24.13% 20.49% 16.71% 34.52% 0.00% 0.00% 1.16% 4.37% 2.97% 10.44%
Short-Term Debt to Total Capital		 9.60% 9.92% 0.00% 3.72% 16.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 14.21% 20.49% 12.98% 17.99% 0.00% 0.00% 1.16% 4.37% 2.97% 10.44%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 150.62% 71.30% 35.56% 44.68% 27.29% 16.38%
Noncontrolling Interests to Total Capital		 0.00% 387.91% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 90.40% -312.04% 79.51% 83.29% 65.48% -50.62% 28.70% 63.28% 50.95% 69.74% 73.18%
Debt to EBITDA		 -0.10 -0.29 -0.38 -0.31 -0.20 0.00 0.00 -0.03 -0.08 -0.07 -0.23
Net Debt to EBITDA		 0.88 1.04 1.43 1.57 0.44 0.00 0.00 3.13 1.72 2.22 2.13
Long-Term Debt to EBITDA		 0.00 -0.17 -0.38 -0.24 -0.10 0.00 0.00 -0.03 -0.08 -0.07 -0.23
Debt to NOPAT		 -0.14 -0.40 -0.53 -0.44 -0.28 0.00 0.00 -0.05 -0.11 -0.10 -0.33
Net Debt to NOPAT		 1.24 1.46 2.02 2.25 0.63 0.00 0.00 4.47 2.57 3.33 3.11
Long-Term Debt to NOPAT		 0.00 -0.24 -0.53 -0.35 -0.15 0.00 0.00 -0.05 -0.11 -0.10 -0.33
Altman Z-Score		 -1.84 -4.87 7.00 0.65 -10.80 -1.21 13.47 16.13 11.54 10.78 7.81
Noncontrolling Interest Sharing Ratio		 0.00% 302.28% 143.71% 0.00% 0.00% 133.15% 102.24% 47.36% 41.65% 35.50% 23.03%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.75 3.47 13.31 9.71 2.92 12.14 14.68 12.93 18.26 15.43 12.65
Quick Ratio		 4.55 3.21 12.55 9.28 2.64 11.96 14.44 12.73 17.93 14.99 12.37
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.64 -8.95 -22 -21 -27 -72 -54 -78 -188 -199 -211
Operating Cash Flow to CapEx		 -5,608.13% -5,902.00% -11,450.00% -6,032.36% -42,923.81% -70,902.38% -21,073.75% -11,773.90% -20,508.91% -45,463.60% -55,836.57%
Free Cash Flow to Firm to Interest Expense		 -54.20 -27.45 -56.98 -24.43 -32.86 -142.62 -18,054.20 -161.36 -101.69 -65.37 -42.73
Operating Cash Flow to Interest Expense		 -48.92 -45.26 -73.54 -30.75 -43.18 -58.62 -18,193.67 -193.08 -99.71 -76.27 -55.86
Operating Cash Flow Less CapEx to Interest Expense		 -49.79 -46.03 -74.19 -31.26 -43.28 -58.70 -18,280.00 -194.72 -100.20 -76.44 -55.96
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.24 0.18 0.10 0.14 0.09 0.01 0.02 0.01 0.00 0.00 0.09
Accounts Receivable Turnover		 3.43 16.80 5.42 11.33 0.00 0.00 0.00 0.00 3.08 0.00 0.00
Inventory Turnover		 13.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.14 3.91 6.74 13.00 7.14 2.52 8.66 2.08 0.21 0.21 57.51
Accounts Payable Turnover		 3.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 106.57 21.73 67.29 32.21 0.00 0.00 0.00 0.00 118.57 0.00 0.00
Days Inventory Outstanding (DIO)		 27.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 113.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 19.75 21.73 67.29 32.21 0.00 0.00 0.00 0.00 118.57 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.68 -2.26 0.99 -0.84 -2.79 -7.60 -9.25 -25 -15 -25 -68
Invested Capital Turnover		 3.26 -4.41 -6.31 110.34 -2.46 -0.20 -0.35 -0.10 -0.02 -0.01 -1.51
Increase / (Decrease) in Invested Capital		 -0.19 -2.94 3.25 -1.83 -1.95 -4.82 -1.65 -16 9.70 -10 -43
Enterprise Value (EV)		 -1.77 63 195 41 -3.29 117 366 898 895 1,010 2,312
Market Capitalization		 7.96 3.60 233 93 15 64 429 1,176 1,145 1,519 2,970
Book Value per Share		 $0.98 ($5.74) $1.73 $1.66 $0.50 ($1.04) $2.48 $6.28 $4.48 $6.09 $6.18
Tangible Book Value per Share		 $0.98 ($5.74) $1.73 $1.66 $0.50 ($1.04) $2.48 $6.28 $4.48 $6.09 $6.18
Total Capital		 12 20 48 62 24 120 188 400 462 692 806
Total Debt		 1.11 4.79 9.92 10 8.30 0.00 0.00 4.65 20 21 84
Total Long-Term Debt		 0.00 2.82 9.92 8.00 4.33 0.00 0.00 4.65 20 21 84
Net Debt		 -9.73 -17 -38 -52 -19 -128 -197 -420 -457 -697 -790
Capital Expenditures (CapEx)		 0.12 0.25 0.25 0.45 0.08 0.04 0.26 0.80 0.90 0.51 0.50
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.46 -3.14 0.53 -1.55 -3.31 -8.70 -10 -27 -18 -27 -51
Debt-free Net Working Capital (DFNWC)		 10 19 48 61 24 119 187 398 460 691 824
Net Working Capital (NWC)		 9.27 17 48 59 20 119 187 398 460 691 824
Net Nonoperating Expense (NNE)		 3.50 5.38 7.94 9.54 12 33 24 36 60 61 88
Net Nonoperating Obligations (NNO)		 -9.73 -17 -38 -52 -19 -128 -197 -420 -457 -697 -790
Total Depreciation and Amortization (D&A)		 0.18 0.30 0.30 -0.14 -0.14 0.58 1.17 0.27 -11 -15 -6.30
Debt-free, Cash-free Net Working Capital to Revenue		 -18.16% -90.39% 13.24% -18.48% -74.20% -828.76% -352.28% -1,508.24% -5,581.85% -8,939.40% -72.15%
Debt-free Net Working Capital to Revenue		 408.63% 545.33% 1,198.38% 726.58% 527.57% 11,327.33% 6,295.21% 22,450.56% 146,446.82% 228,671.19% 1,162.38%
Net Working Capital to Revenue		 365.09% 488.70% 1,198.38% 699.22% 438.44% 11,327.33% 6,295.21% 22,450.56% 146,446.82% 228,671.19% 1,162.38%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($315.00) ($263.70) ($20.70) ($16.50) ($20.10) ($31.13) ($6.66) ($4.05) ($5.31) ($412.71) ($446.62)
Adjusted Weighted Average Basic Shares Outstanding		 47.60K 1.42M 2.01M 2.06M 3.54M 7.23M 11.92M 32.09M 44.76M 68.19M 85.08M
Adjusted Diluted Earnings per Share		 ($315.00) ($263.70) ($20.70) ($16.50) ($20.10) ($31.13) ($6.66) ($4.05) ($5.31) ($412.71) ($446.62)
Adjusted Weighted Average Diluted Shares Outstanding		 47.60K 1.42M 2.01M 2.06M 3.54M 7.23M 11.92M 32.09M 44.76M 68.19M 85.08M
Adjusted Basic & Diluted Earnings per Share		 ($315.00) ($263.70) ($20.70) ($16.50) ($20.10) ($31.13) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 35.96K 48.09K 1.28M 1.97M 2.09M 3.56M 25.91M 42.90M 62.77M 81.48M 102.21M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.83 -12 -19 -23 -29 -77 -56 -94 -178 -209 -254
Normalized NOPAT Margin		 -308.55% -341.99% -463.96% -276.16% -658.72% -7,358.67% -1,883.55% -5,305.46% -56,724.52% -69,312.75% -359.04%
Pre Tax Income Margin		 -446.34% -497.93% -672.37% -404.92% -959.74% -10,560.76% -2,680.16% -7,329.23% -75,711.47% -89,387.09% -483.57%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -79.34 -52.11 -69.27 -37.90 -50.27 -217.28 -26,576.00 -276.35 -137.76 -98.17 -73.78
NOPAT to Interest Expense		 -55.54 -36.48 -48.49 -26.53 -35.19 -152.10 -18,603.20 -193.44 -96.43 -68.72 -51.41
EBIT Less CapEx to Interest Expense		 -80.21 -52.87 -69.92 -38.41 -50.37 -217.37 -26,662.33 -277.99 -138.25 -98.34 -73.88
NOPAT Less CapEx to Interest Expense		 -56.41 -37.24 -49.13 -27.04 -35.29 -152.18 -18,689.53 -195.08 -96.92 -68.89 -51.51
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -6.96% -9.29% -0.18% -5.58% -10.42% -16.99% -4.96% -9.98% -5.45%

Quarterly Metrics And Ratios for Viridian Therapeutics

This table displays calculated financial ratios and metrics derived from Viridian Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 102,206,571.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 102,206,571.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -1.03
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -93.97% -52.91% 0.00% 0.00% 19.44% -15.29% 0.00% 4.17% 81,958.14% 83.33% 95.83%
EBITDA Growth		 -81.61% -49.20% 19.92% -23.12% -61.85% -21.84% -59.17% -41.63% 53.21% -37.36% -15.55%
EBIT Growth		 -71.98% -45.68% 22.87% -21.78% -62.97% -22.37% -67.93% -47.90% 52.72% -40.33% -16.41%
NOPAT Growth		 -71.98% -45.68% 22.87% -21.78% -62.97% -22.37% -67.93% -47.90% 52.07% -40.33% -23.76%
Net Income Growth		 -64.89% -46.03% 28.77% -18.03% -60.91% -19.24% -79.05% -54.99% 54.88% -50.96% -20.70%
EPS Growth		 -26.74% -36,613.38% -4,836.65% 19.69% -5.50% 21.40% -46.89% -29.73% 61.08% -34.71% -3.59%
Operating Cash Flow Growth		 -88.62% -11.63% 27.03% -1.87% -73.68% -92.98% -104.88% -63.65% -24.97% 67.61% -29.14%
Free Cash Flow Firm Growth		 -256.78% -218.50% -16.01% -0.44% 3.36% 14.60% -36.11% -61.47% -102.10% 15.73% 17.68%
Invested Capital Growth		 46.72% 39.04% 44.56% -57.21% -167.43% -67.49% -11.10% -26.98% 230.68% -169.29% -245.49%
Revenue Q/Q Growth		 0.00% 136.11% -57.65% 0.00% 19.44% 67.44% -50.00% 4.17% 93,993.33% -99.81% 6.82%
EBITDA Q/Q Growth		 13.64% -38.72% 18.82% -26.60% -13.53% -4.43% -6.04% -12.65% 62.27% -204.94% 10.72%
EBIT Q/Q Growth		 13.58% -39.54% 21.80% -29.14% -15.64% -4.78% -7.31% -13.74% 62.95% -210.29% 10.95%
NOPAT Q/Q Growth		 13.58% -39.54% 21.80% -29.14% -15.64% -4.78% -7.31% -13.74% 62.52% -206.77% 5.36%
Net Income Q/Q Growth		 13.44% -40.29% 27.40% -33.89% -18.00% -3.96% -9.01% -15.90% 65.65% -247.86% 12.84%
EPS Q/Q Growth		 14.17% -47,728.44% 84.75% -29.11% -12.75% -35,530.43% 71.51% -15.61% 65.73% -221.31% 18.64%
Operating Cash Flow Q/Q Growth		 13.78% 2.52% -19.01% -1.85% -47.00% -8.31% -26.35% 18.65% -12.26% 71.93% -403.72%
Free Cash Flow Firm Q/Q Growth		 -3.85% -35.36% 20.59% 10.02% 0.08% -19.61% -26.56% -6.75% -25.07% 50.13% -23.64%
Invested Capital Q/Q Growth		 31.29% -60.57% 31.79% -108.90% -16.89% -0.56% 54.76% -138.77% 220.29% -307.23% 41.96%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -74,362.50% -43,689.41% -83,738.89% -106,013.89% -100,761.63% -62,844.44% -133,286.11% -144,137.33% -57.80% -94,228.79% -78,756.74%
Operating Margin		 -71,144.44% -42,045.88% -77,634.72% -100,259.72% -97,069.77% -60,743.75% -130,369.44% -142,356.00% -56.70% -92,991.67% -82,389.36%
EBIT Margin		 -71,144.44% -42,045.88% -77,634.72% -100,259.72% -97,069.77% -60,743.75% -130,369.44% -142,356.00% -56.06% -92,991.67% -77,525.53%
Profit (Net Income) Margin		 -66,194.44% -39,329.41% -67,419.44% -90,268.06% -89,173.26% -55,364.58% -120,711.11% -134,313.33% -49.03% -91,178.03% -74,397.87%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.04% 93.54% 86.84% 90.03% 91.87% 91.14% 92.59% 94.35% 87.46% 98.05% 95.97%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -726.18% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -725.09% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 720.45% 0.00% 0.00%
Return on Equity (ROE)		 -62.57% -56.80% -46.75% -53.97% -51.88% -48.48% -51.95% -65.88% -5.73% -49.16% -58.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -873.39% 0.00% 0.00%
Operating Return on Assets (OROA)		 -93.40% -28.53% -58.93% 0.00% -2.47% -29.76% -60.98% -74.35% -5.88% -8,025.68% -7,583.40%
Return on Assets (ROA)		 -86.90% -26.69% -51.18% 0.00% -2.27% -27.12% -56.46% -70.15% -5.15% -7,869.16% -7,277.46%
Return on Common Equity (ROCE)		 -37.54% -33.14% -29.99% -32.60% -34.93% -31.27% -34.94% -41.37% -3.94% -37.84% -43.10%
Return on Equity Simple (ROE_SIMPLE)		 -76.40% 0.00% -37.44% -43.08% -36.34% 0.00% -51.01% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -36 -50 -39 -51 -58 -61 -66 -75 -28 -86 -81
NOPAT Margin		 -49,801.11% -29,432.12% -54,344.31% -70,181.81% -67,948.84% -42,520.63% -91,258.61% -99,649.20% -39.69% -65,094.17% -57,672.55%
Net Nonoperating Expense Percent (NNEP)		 -3.28% -3.84% -1.96% -3.29% -3.56% -3.21% -3.51% -4.76% -1.10% -4.63% -3.65%
Return On Investment Capital (ROIC_SIMPLE)		 - -10.82% -6.49% - - -8.85% -10.51% -13.94% -5.35% -10.66% -11.25%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 29,043.06% 19,407.65% 20,868.06% 22,313.89% 16,753.49% 10,822.22% 23,754.17% 26,954.67% 34.47% 25,510.61% 27,431.91%
R&D to Revenue		 42,201.39% 22,680.59% 56,866.67% 78,045.83% 80,416.28% 49,971.53% 106,715.28% 115,501.33% 122.23% 67,581.06% 55,057.45%
Operating Expenses to Revenue		 71,244.44% 42,088.24% 77,734.72% 100,359.72% 97,169.77% 60,793.75% 130,469.44% 142,456.00% 156.70% 93,091.67% 82,489.36%
Earnings before Interest and Taxes (EBIT)		 -51 -71 -56 -72 -83 -87 -94 -107 -40 -123 -109
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -54 -74 -60 -76 -87 -90 -96 -108 -41 -124 -111
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.51 4.86 2.41 2.52 2.80 3.15 2.64 3.50 5.61 5.03 3.97
Price to Tangible Book Value (P/TBV)		 4.51 4.86 2.41 2.52 2.80 3.15 2.64 3.50 5.61 5.03 3.97
Price to Revenue (P/Rev)		 1,326.54 3,647.53 2,385.44 0.00 103,821.12 5,028.17 3,637.14 3,739.86 24.89 41.92 28.19
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 44.94 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1,013.48 2,849.28 1,366.92 0.00 64,975.98 3,345.67 2,223.03 2,580.24 20.92 32.63 20.52
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.07 0.05 0.03 0.04 0.03 0.03 0.03 0.04 0.04 0.12 0.14
Long-Term Debt to Equity		 0.07 0.05 0.03 0.03 0.03 0.03 0.03 0.02 0.04 0.12 0.14
Financial Leverage		 -1.04 -1.05 -1.03 -1.04 -1.04 -1.04 -1.02 -1.05 -0.99 -1.07 -1.04
Leverage Ratio		 1.11 1.11 1.09 1.11 1.11 1.11 1.09 1.12 1.11 1.18 1.17
Compound Leverage Factor		 1.03 1.03 0.95 1.00 1.02 1.01 1.01 1.06 0.97 1.16 1.12
Debt to Total Capital		 6.59% 4.37% 3.37% 3.72% 2.82% 2.97% 3.31% 3.88% 3.99% 10.44% 11.98%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.54% 0.00% 0.00% 0.00% 1.57% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 6.59% 4.37% 3.37% 3.18% 2.82% 2.97% 3.31% 2.30% 3.99% 10.44% 11.98%
Preferred Equity to Total Capital		 44.44% 44.68% 33.13% 36.32% 25.95% 27.29% 30.21% 35.24% 36.06% 16.38% 18.28%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 48.97% 50.95% 63.50% 59.96% 71.24% 69.74% 66.48% 60.88% 59.96% 73.18% 69.75%
Debt to EBITDA		 -0.08 -0.08 -0.08 -0.08 -0.07 -0.07 -0.06 -0.05 -0.06 -0.23 -0.22
Net Debt to EBITDA		 1.22 1.72 2.37 2.08 2.46 2.22 1.76 1.42 1.40 2.13 1.75
Long-Term Debt to EBITDA		 -0.08 -0.08 -0.08 -0.07 -0.07 -0.07 -0.06 -0.03 -0.06 -0.23 -0.22
Debt to NOPAT		 -0.12 -0.11 -0.12 -0.12 -0.10 -0.10 -0.09 -0.08 -0.09 -0.33 -0.32
Net Debt to NOPAT		 1.80 2.57 3.56 3.14 3.70 3.33 2.61 2.09 2.05 3.11 2.50
Long-Term Debt to NOPAT		 -0.12 -0.11 -0.12 -0.10 -0.10 -0.10 -0.09 -0.05 -0.09 -0.33 -0.32
Altman Z-Score		 6.67 12.77 10.68 7.55 12.65 11.73 10.03 7.83 12.28 8.70 6.03
Noncontrolling Interest Sharing Ratio		 40.00% 41.65% 35.86% 39.59% 32.67% 35.50% 32.74% 37.20% 31.21% 23.03% 25.87%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.93 18.26 23.99 15.82 18.55 15.43 19.49 11.01 11.28 12.65 15.15
Quick Ratio		 13.47 17.93 23.47 15.54 18.21 14.99 18.88 10.71 9.68 12.37 14.71
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -44 -60 -47 -43 -43 -51 -65 -69 -86 -43 -53
Operating Cash Flow to CapEx		 -9,649.26% -79,166.67% 0.00% -44,286.54% -23,107.85% -64,326.32% -107,736.05% -179,459.52% -66,622.83% -9,897.50% -520,234.78%
Free Cash Flow to Firm to Interest Expense		 -73.55 -65.21 -80.80 -71.49 -42.48 -59.45 -110.17 -134.08 -153.91 -13.07 -15.35
Operating Cash Flow to Interest Expense		 -64.97 -41.48 -77.04 -77.15 -67.44 -85.47 -158.11 -146.64 -151.09 -7.22 -34.56
Operating Cash Flow Less CapEx to Interest Expense		 -65.65 -41.54 -77.04 -77.32 -67.73 -85.60 -158.26 -146.72 -151.32 -7.30 -34.57
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.09 0.10
Accounts Receivable Turnover		 2.02 3.08 3.36 0.00 0.24 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.38 0.21 0.25 0.00 0.01 0.21 0.22 0.23 58.62 57.51 61.88
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 180.69 118.57 108.74 0.00 1,512.14 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 180.69 118.57 108.74 0.00 1,512.14 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -9.43 -15 -10 -22 -25 -25 -11 -27 33 -68 -40
Invested Capital Turnover		 -0.04 -0.02 -0.03 0.00 0.00 -0.01 -0.03 -0.01 18.30 -1.51 -2.77
Increase / (Decrease) in Invested Capital		 8.27 9.70 8.30 -7.85 -16 -10 -1.15 -5.82 58 -43 -28
Enterprise Value (EV)		 512 895 528 479 910 1,010 671 787 1,481 2,312 1,456
Market Capitalization		 670 1,145 921 830 1,453 1,519 1,098 1,141 1,762 2,970 1,999
Book Value per Share		 $3.40 $4.48 $6.23 $5.16 $8.12 $6.09 $5.10 $4.00 $3.85 $6.18 $4.93
Tangible Book Value per Share		 $3.40 $4.48 $6.23 $5.16 $8.12 $6.09 $5.10 $4.00 $3.85 $6.18 $4.93
Total Capital		 304 462 603 550 728 692 625 536 524 806 723
Total Debt		 20 20 20 20 21 21 21 21 21 84 87
Total Long-Term Debt		 20 20 20 17 21 21 21 12 21 84 87
Net Debt		 -293 -457 -593 -551 -733 -697 -616 -543 -470 -790 -676
Capital Expenditures (CapEx)		 0.40 0.05 0.00 0.10 0.29 0.11 0.09 0.04 0.13 0.24 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -18 -12 -24 -27 -27 -13 -29 30 -51 -29
Debt-free Net Working Capital (DFNWC)		 301 460 601 548 726 691 624 535 521 824 733
Net Working Capital (NWC)		 301 460 601 545 726 691 624 526 521 824 733
Net Nonoperating Expense (NNE)		 12 17 9.41 14 18 18 21 26 6.59 34 24
Net Nonoperating Obligations (NNO)		 -293 -457 -593 -551 -733 -697 -616 -543 -470 -790 -676
Total Depreciation and Amortization (D&A)		 -2.32 -2.79 -4.40 -4.14 -3.18 -3.03 -2.10 -1.34 -1.23 -1.63 -1.74
Debt-free, Cash-free Net Working Capital to Revenue		 -2,458.42% -5,581.85% -3,237.31% 0.00% -194,621.43% -8,939.40% -4,345.03% -9,428.20% 42.83% -72.15% -41.23%
Debt-free Net Working Capital to Revenue		 59,523.17% 146,446.82% 155,619.43% 0.00% 5,185,664.29% 228,671.19% 206,460.60% 175,278.69% 736.30% 1,162.38% 1,033.50%
Net Working Capital to Revenue		 59,523.17% 146,446.82% 155,619.43% 0.00% 5,185,664.29% 228,671.19% 206,460.60% 172,513.11% 736.30% 1,162.38% 1,033.50%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.09) ($521.33) ($0.79) ($1.02) ($1.15) ($409.75) ($116.75) ($134.97) ($46.26) ($148.64) ($120.94)
Adjusted Weighted Average Basic Shares Outstanding		 43.65M 45.00M 61.10M 63.85M 66.42M 68.19M 81.62M 81.87M 82.06M 85.08M 102.43M
Adjusted Diluted Earnings per Share		 ($1.09) ($521.33) ($0.79) ($1.02) ($1.15) ($409.75) ($116.75) ($134.97) ($46.26) ($148.64) ($120.94)
Adjusted Weighted Average Diluted Shares Outstanding		 43.65M 45.00M 61.10M 63.85M 66.42M 68.19M 81.62M 81.87M 82.06M 85.08M 102.43M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 52.59M 62.77M 63.82M 63.89M 79.21M 81.48M 81.59M 81.66M 95.44M 102.21M 103.07M
Normalized Net Operating Profit after Tax (NOPAT)		 -36 -50 -39 -51 -58 -61 -66 -75 -28 -86 -81
Normalized NOPAT Margin		 -49,801.11% -29,432.12% -54,344.31% -70,181.81% -67,948.84% -42,520.63% -91,258.61% -99,649.20% -39.69% -65,094.17% -57,672.55%
Pre Tax Income Margin		 -66,194.44% -39,329.41% -67,419.44% -90,268.06% -89,173.26% -55,364.58% -120,711.11% -134,313.33% -49.03% -91,178.03% -74,397.87%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -85.37 -78.03 -95.22 -120.92 -83.15 -101.95 -160.18 -207.72 -70.64 -37.33 -31.57
NOPAT to Interest Expense		 -59.76 -54.62 -66.66 -84.64 -58.20 -71.36 -112.13 -145.40 -50.02 -26.13 -23.49
EBIT Less CapEx to Interest Expense		 -86.05 -78.09 -95.22 -121.09 -83.44 -102.08 -160.33 -207.80 -70.87 -37.41 -31.58
NOPAT Less CapEx to Interest Expense		 -60.43 -54.68 -66.66 -84.82 -58.50 -71.50 -112.27 -145.48 -50.24 -26.21 -23.50
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.43% -4.96% -10.17% -9.77% -14.56% -9.98% -5.44% -4.85% -0.57% -5.45% -5.12%

Financials Breakdown Chart

Key Financial Trends

Here is Viridian Therapeutics, Inc. (VRDN) summarized from the last four years of quarterly statements. The company shows a funding-heavy profile with ongoing R&D investment, large equity financing activity, and persistent cash burn, balanced by a strong equity cushion on the balance sheet. The key trends you should consider as a retail investor are highlighted below.

  • Strong liquidity infusion via equity financing in 2025: In Q4 2025, Issuance of Common Equity was $337.3M and Net Cash From Financing Activities was $405.9M, materially boosting liquidity to fund operations and development.
  • Healthy balance-sheet equity cushion: As of 2025 Q3, Total Liabilities were about $74.2M, while Total Equity was roughly $503M, indicating a substantial equity cushion relative to debt.
  • Rising cash reserves during 2025: Cash & Equivalents rose to about $169.6M in 2025 Q3 (up from ~$117.3M in Q2 2025), indicating improved near-term liquidity runway.
  • Ongoing emphasis on pipeline through R&D investment: Research & Development expenses remain very high (example: $89.2M in Q4 2025), signaling continued focus on product development despite lack of current profitability.
  • Equity dilution risk from recurring financings: Ongoing common equity issuances have likely increased diluted shares (e.g., Diluted Shares Outstanding around 85.1M in Q4 2025), which may dilute existing holders.
  • Historical restatements noted in earlier years: Several quarters show restatements (e.g., Q3 2024, Q2 2024, Q1 2024), introducing some historical data uncertainty, though 2025 data appear to have stabilized.
  • Chronic net losses across quarters: Net income/Net income continuing are negative in multiple periods (e.g., Q4 2025 net income of -$120.36M), reflecting ongoing losses.
  • Significant operating cash burn: Net Cash From Operating Activities remained negative across many quarters (e.g., Q4 2025: -$23.8M; Q3 2025: -$84.6M), indicating substantial cash burn before financing.
  • Large investing outflows concentrated in investments: Net Cash From Investing Activities often shows sizable outflows (e.g., Q4 2025: -$339.4M; Q4 2025 investing activities include large purchases of investments), pressuring near-term liquidity without financing.
  • Modest near-term revenue and high dependency on financing: Operating revenue is typically in the low range (tens to hundreds of thousands per quarter), while profitability remains elusive, making the business highly reliant on ongoing financing to fund R&D and operations.
05/14/26 04:57 PM ETAI Generated. May Contain Errors.

Viridian Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Viridian Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Viridian Therapeutics' net income appears to be on an upward trend, with a most recent value of -$342.60 million in 2025, rising from -$11.33 million in 2015. The previous period was -$269.95 million in 2024. See where experts think Viridian Therapeutics is headed by visiting Viridian Therapeutics' forecast page.

Viridian Therapeutics' total operating income in 2025 was -$363.40 million, based on the following breakdown:
  • Total Gross Profit: $70.85 million
  • Total Operating Expenses: $434.24 million

Over the last 10 years, Viridian Therapeutics' total revenue changed from $2.54 million in 2015 to $70.85 million in 2025, a change of 2,691.5%.

Viridian Therapeutics' total liabilities were at $177.25 million at the end of 2025, a 150.5% increase from 2024, and a 7,012.8% increase since 2015.

In the past 10 years, Viridian Therapeutics' cash and equivalents has ranged from $10.83 million in 2015 to $212.38 million in 2025, and is currently $212.38 million as of their latest financial filing in 2025.

Over the last 10 years, Viridian Therapeutics' book value per share changed from 0.98 in 2015 to 6.18 in 2025, a change of 531.7%.


Related Companies

Financial statements for NASDAQ:VRDN last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Millionaire warns: Move your money before May 15
Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2...
Brownstone Research | Sponsoredtc pixel
Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX
The Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...
InvestorPlace | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
Musk's acquisition pattern points to ONE stock
Musk needed solar - he acquired SolarCity. Needed data - he bought Twitter. The pattern is clear: when a suppl...
Behind the Markets | Sponsoredtc pixel